PMID- 28264635
OWN - NLM
STAT- MEDLINE
DCOM- 20190426
LR  - 20190426
IS  - 1814-1412 (Electronic)
IS  - 1562-2975 (Linking)
VI  - 19
IP  - 8
DP  - 2018 Dec
TI  - Lurasidone compared to other atypical antipsychotic monotherapies for bipolar 
      depression: A systematic review and network meta-analysis.
PG  - 586-601
LID - 10.1080/15622975.2017.1285050 [doi]
AB  - OBJECTIVES: To assess the efficacy and tolerability of lurasidone versus other 
      atypical antipsychotic monotherapy agents in patients with bipolar depression, 
      using a Bayesian network meta-analysis. METHODS: Fourteen randomised clinical 
      trials (6221 patients) of lurasidone, quetiapine (extended release and immediate 
      release), aripiprazole, olanzapine, and ziprasidone for bipolar depression were 
      included. Efficacy assessments included change in the Montgomery-Asberg 
      Depression Rating Scale (MADRS), rates of response (>/=50% improvement in MADRS) 
      and remission (MADRS </=12 at study endpoint), and change in the Clinical Global 
      Impressions-Bipolar Disorder-Severity (CGI-BP-S) scale. Tolerability outcomes 
      included weight, somnolence, extrapyramidal symptoms (EPS), and all-cause 
      discontinuation. Changes from baseline or odds ratios (OR) with 95% credible 
      intervals (CrI) were evaluated. RESULTS: Improvement in the MADRS associated with 
      lurasidone treatment was significantly greater than placebo (-4.70, 95%CrI: 
      -7.20, -2.21), aripiprazole (-3.62, 95%CrI: -7.04, -0.20), and ziprasidone 
      (-3.38, 95%CrI: -6.68, -0.11), but not olanzapine (-0.15, 95%CrI: -3.12, 2.74) or 
      quetiapine (0.10, 95%CrI: -2.68, 2.84). Results for improvement in the CGI-BP-S, 
      and for response and remission were similar. Lurasidone was associated with less 
      weight gain than olanzapine (-2.54 kg, 95%CrI: -3.42, -1.67) and quetiapine 
      (-0.83kg, 95%CrI: -1.59, -0.08); and with lower rates of somnolence than 
      quetiapine (OR: 0.33, 95%CrI: 0.11, 0.82) and ziprasidone (OR: 0.34, 95%CrI: 
      0.09, 0.93). No significant differences among atypical antipsychotic agents were 
      observed in rates of discontinuation or in rates of EPS. CONCLUSIONS: In this 
      network meta-analysis, lurasidone was found to be more efficacious than 
      aripiprazole and ziprasidone, and was associated with less weight gain than 
      quetiapine and olanzapine and less somnolence than quetiapine and ziprasidone.
FAU - Ostacher, Michael
AU  - Ostacher M
AD  - a Department of Psychiatry and Behavioral Sciences , Stanford University School 
      of Medicine , Palo Alto , CA , USA.
FAU - Ng-Mak, Daisy
AU  - Ng-Mak D
AD  - b Global HEOR, Sunovion Pharmaceuticals Inc , Marlborough , MA , USA.
FAU - Patel, Pankaj
AU  - Patel P
AD  - c Health Outcomes, Kantar Health , New York , NY , USA.
FAU - Ntais, Dionysios
AU  - Ntais D
AD  - d Real-World Evidence Solutions, QuintilesIMS , London , UK.
FAU - Schlueter, Max
AU  - Schlueter M
AD  - e Health Economics & Outcomes Research , Real-World Evidence Solutions, 
      QuintilesIMS , London , UK.
FAU - Loebel, Antony
AU  - Loebel A
AD  - f Sunovion Pharmaceuticals Inc , Fort Lee , NJ , USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20170307
PL  - England
TA  - World J Biol Psychiatry
JT  - The world journal of biological psychiatry : the official journal of the World 
      Federation of Societies of Biological Psychiatry
JID - 101120023
RN  - 0 (Antipsychotic Agents)
RN  - O0P4I5851I (Lurasidone Hydrochloride)
SB  - IM
MH  - Antipsychotic Agents/adverse effects/*pharmacology
MH  - Bipolar Disorder/*drug therapy
MH  - Humans
MH  - Lurasidone Hydrochloride/adverse effects/*pharmacology
MH  - *Network Meta-Analysis
OTO - NOTNLM
OT  - Lurasidone
OT  - atypical antipsychotics
OT  - bipolar depression
OT  - network meta-analysis
OT  - systematic review
EDAT- 2017/03/08 06:00
MHDA- 2019/04/27 06:00
CRDT- 2017/03/08 06:00
PHST- 2017/03/08 06:00 [pubmed]
PHST- 2019/04/27 06:00 [medline]
PHST- 2017/03/08 06:00 [entrez]
AID - 10.1080/15622975.2017.1285050 [doi]
PST - ppublish
SO  - World J Biol Psychiatry. 2018 Dec;19(8):586-601. doi: 
      10.1080/15622975.2017.1285050. Epub 2017 Mar 7.